Brief: Krystal Biotech Announces First Patient Dosed In Phase 1 Clinical Trial Of KB407 For The Treatment Of Cystic Fibrosis
03/07/2023 12:02
July 3 (Reuters) - Krystal Biotech Inc KRYS.O :
* KRYSTAL BIOTECH ANNOUNCES FIRST PATIENT DOSED IN PHASE 1
CLINICAL TRIAL OF KB407 FOR THE TREATMENT OF CYSTIC FIBROSIS
* KRYSTAL BIOTECH INC - LOOK FORWARD TO CONTINUED ENROLLMENT
INTO
PHASE 1 STUDY WITH ANTICIPATED DATA IN 2024
* KRYSTAL BIOTECH INC-LOOK FORWARD TO CONTINUED ENROLLMENT
INTO
PHASE 1 STUDY OF OF KB407 WITH ANTICIPATED DATA IN 2024
Source text for Eikon: ID:nGNX95lVbS
Further company coverage: KRYS.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion